EcoDrugPlus

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSOKIG00005027854
Gene Symbol: MAPK14
3 Cross references
218 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSOKIG00005009037
Gene Symbol: MAPK14
3 Cross references
200 Possible Orthologues:

Mitogen-Activated Protein Kinase 14a

Ensembl ID : ENSOKIG00005004454
Gene Symbol: LOC109908345
3 Cross references
201 Possible Orthologues:

Mitogen-Activated Protein Kinase 14a-Like

Ensembl ID : ENSOKIG00005000491
Gene Symbol: LOC109890804
2 Cross references
217 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSOKIG00005019465
Gene Symbol: LOC109870023
3 Cross references
219 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSOKIG00005029668
Gene Symbol: LOC109899560
3 Cross references
215 Possible Orthologues:

Mitogen-Activated Protein Kinase 8-Like

Ensembl ID : ENSOKIG00005031589
Gene Symbol: LOC109889737
3 Cross references
215 Possible Orthologues:

Mitogen-Activated Protein Kinase 8-Like

Ensembl ID : ENSOKIG00005034755
Gene Symbol: LOC109865387
3 Cross references
219 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSOKIG00005018580
Gene Symbol: LOC109864614
2 Cross references
201 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSOKIG00005048550
Gene Symbol: MAPK9
3 Cross references
165 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSOKIG00005019896
Gene Symbol: MAP2K1
3 Cross references
214 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2a

Ensembl ID : ENSOKIG00005021116
Gene Symbol: MAP2K2A
1 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).